8-K: Acrivon Therapeutics Announces Positive Phase 2 Clinical Data and Accelerated Pipeline Progress

Acrivon Therapeutics reports a 50% confirmed objective response rate in OncoSignature-positive patients in a Phase 2 trial of ACR-368 and accelerates the IND filing for ACR-2316.

Summary

• Acrivon Therapeutics announced initial positive clinical data from its Phase 2b trial of ACR-368 in ovarian and endometrial cancers.
• The trial showed a 50% confirmed objective response rate (ORR) in OncoSignature-positive patients.
• All confirmed responders are still on treatment, and the median duration of response (DoR) has not yet been reached.
• The company's AP3 platform successfully predicted which patients would respond to ACR-368, with a statistically significant difference in response between OncoSignature-positive and negative groups (p-value = 0.0038).
• In OncoSignature-negative patients, the combination of ACR-368 with ultra-low dose gemcitabine showed encouraging signs of clinical activity, with 8 out of 16 patients achieving stable disease.
• Acrivon is also advancing ACR-2316, a dual WEE1/PKMYT1 inhibitor, with an accelerated IND filing expected in Q3 2024 and a potential clinical study initiation in Q4 2024.
• The company has a pro forma cash balance of approximately $234 million as of March 31, 2024, which is expected to fund operations into the second half of 2026.

Sentiment

Score: 9

Explanation: The document presents very positive clinical data, strong validation of the AP3 platform, and accelerated pipeline progress, all of which are highly favorable for the company's future prospects.

Positives

• The 50% confirmed objective response rate in OncoSignature-positive patients is a significant improvement over standard of care for these cancers.
• The AP3 platform has shown strong predictive capabilities, successfully identifying patients likely to respond to ACR-368.
• The accelerated timeline for ACR-2316's IND filing indicates rapid progress in the company's pipeline.
• The company has a strong cash position, providing financial stability for the next two years.

Negatives

• The preliminary cash balance of $110 million as of March 31, 2024, is subject to change and may differ materially from the final figure.
• The data presented is from a small sample size of 26 patients, which may limit the generalizability of the results.
• The OncoSignature-negative arm of the trial did not show any objective responses to ACR-368 monotherapy.

Risks

• The preliminary cash balance is subject to change and may differ materially from the final figure.
• The clinical trial data is based on a small sample size, which may not be representative of the broader patient population.
• The company's future success depends on the continued development and regulatory approval of its drug candidates.
• There are risks associated with the development of new drugs, including potential safety issues and lack of efficacy.

Future Outlook

The company expects its pro forma cash balance to fund operations into the second half of 2026. They also anticipate an IND filing for ACR-2316 in Q3 2024 and a clinical trial initiation in Q4 2024.

Management Comments

• Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon Therapeutics, stated that the initial clinical data highlights the power of their AP3 precision medicine platform.
• Kristina Masson, Ph.D., M.B.A., co-founder and executive vice president of business operations at Acrivon Therapeutics, Inc., mentioned the accelerated timelines for ACR-2316's IND filing and the potential of the drug to address unmet treatment needs.

Industry Context

This announcement is significant in the precision oncology space, as it demonstrates the potential of proteomics-based patient selection to improve treatment outcomes. The development of a dual WEE1/PKMYT1 inhibitor also addresses a key area of unmet need in cancer therapy.

Comparison to Industry Standards

• The 50% ORR in OncoSignature-positive patients is significantly higher than the standard of care for platinum-resistant ovarian cancer, which is around 12% ORR.
• The 60% ORR in endometrial cancer patients is also a notable improvement over the standard of care, which is approximately 9% ORR.
• Mirvetuximab, a recently approved drug for ovarian cancer, has an ORR of around 35% in a subset of patients, highlighting the potential of Acrivon's approach to improve patient outcomes.
• The company's approach of using a predictive biomarker to select patients for treatment is similar to other precision medicine companies, but Acrivon's AP3 platform is unique in its use of proteomics.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical data and accelerated pipeline progress.
• Patients with ovarian and endometrial cancers may benefit from the development of new and more effective treatments.
• Employees may be motivated by the company's progress and potential for future success.
• The company's success could lead to increased collaboration with other pharmaceutical companies and research institutions.

Next Steps

• Acrivon plans to continue the Phase 2b trial of ACR-368.
• The company will proceed with IND filing for ACR-2316 in Q3 2024.
• They anticipate initiating a clinical trial for ACR-2316 in Q4 2024.
• The company will continue to develop and refine its AP3 platform.

Key Dates

Keywords

Acrivon Therapeutics, ACR-368, ACR-2316, OncoSignature, AP3, Precision Medicine, Ovarian Cancer, Endometrial Cancer, WEE1, PKMYT1, Clinical Trial, Biomarker, Drug Development